Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

被引:8
|
作者
Yin, Hanlin [1 ]
Distler, Oliver [2 ]
Shen, Lichong [1 ]
Xu, Xiaojiang [3 ]
Yuan, Ye [4 ,5 ]
Li, Rui [1 ]
Liu, Bei [1 ]
Li, Qianqian [1 ]
Huang, Qianru [1 ,6 ]
Xie, Feng [1 ,6 ]
Zhang, Zhiliang [1 ,7 ]
Liang, Rui [1 ,6 ]
Dai, Xueyu [6 ]
Chen, Xiaoxiang [1 ,8 ]
Li, Bin [6 ]
Yan, Qingran [1 ]
Lu, Liangjing [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai, Peoples R China
[2] Univ Zurich, Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland
[3] Tulane Univ, Dept Pathol & Lab Med, Sch Med, New Orleans, LA USA
[4] Shanghai Jiao Tong Univ, Inst Image Proc & Pattern Recognit, Shanghai, Peoples R China
[5] Minist Educ China, Key Lab Syst Control & Informat Proc, Shanghai, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med,Dept Thorac Surg,Dept Immunol & Microbiol, Dept Resp & Crit Care Med,Shanghai Inst Immunol, Ruijin Hosp,Jiading New Town Ctr,Ctr Immune Relate, Shanghai, Peoples R China
[7] Ningbo Hangzhou Bay Hosp, Dept Plast & Aesthet Surg, Ningbo, Zhejiang, Peoples R China
[8] Nantong Univ, Nantong Hosp,Sch Med, Nantong Peoples Hosp 1,Shanghai Jiao Tong Univ, Dept Rheumatol,Affiliated Hosp 2,Renji Hosp, Nantong 226006, Peoples R China
关键词
GENE-EXPRESSION; DOUBLE-BLIND; SKIN; ACTIVATION; INDUCTION; ALPHA; CELLS; ASSOCIATION; SCLERODERMA; RECEPTOR;
D O I
10.1002/art.42662
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveInterferon (IFN)-1 signatures are a hallmark of patients with systemic sclerosis (SSc). However, its significance in clinical stratification and contribution to deterioration still need to be better understood.MethodsFor hypothesis generation, we performed single-cell RNA sequencing (scRNA-seq) on skin biopsies (four patients with SSc and two controls) using the BD Rhapsody platform. Two publicly available data sets of skin scRNA-seq were used for validation (GSE138669: 12 patients with diffuse cutaneous SSc [dcSSc] and 10 controls; GSE195452: 52 patients with dcSSc and 41 patients with limited cutaneous SSc [lcSSc] and 54 controls). The IFN-1 signature was mapped, functionally investigated in a bleomycin plus IFN alpha-2 adenovirus-associated virus (AAV)-induced model and verified in an SSc cohort (n = 61).ResultsThe discovery and validation data sets showed similar findings. Endothelial cells (ECs) had the most prominent IFN-1 signature among dermal nonimmune cells. The EC IFN-1 signature was increased both in patients with SSc versus controls and in patients with dcSSc versus those with lcSSc. Among EC subclusters, the IFN-1 signature was statistically higher in the capillary ECs of patients with dcSSc, which was higher than those in patients with lcSSc, which in turn was higher than those in healthy controls (HCs). Endothelial-to-mesenchymal transition (EndoMT) scores increased in parallel. Deteriorated bleomycin-induced dermal fibrosis, EndoMT, and perivascular fibrosis and caused blood vessel loss with EC apoptosis. Vascular myxovirus resistance (MX) 1, an IFN-1 response protein, was significantly increased both in total SSc versus HC skin and in dcSSc versus lcSSc skin. Baseline vascular MX1 performed similarly to skin score in predicting disease progression over 6 to 34 months in total SSc and was superior in the dcSSc subpopulation.ConclusionThe EC IFN-1 signature distinguished SSc skin subtypes and disease progression and may contribute to vasculopathy and fibrosis.image image
引用
收藏
页码:78 / 91
页数:14
相关论文
共 50 条
  • [21] Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis
    Ikawa, Tetsuya
    Miyagawa, Takuya
    Fukui, Yuki
    Toyama, Satoshi
    Omatsu, Jun
    Awaji, Kentaro
    Norimatsu, Yuta
    Watanabe, Yusuke
    Yoshizaki, Ayumi
    Sato, Shinichi
    Asano, Yoshihide
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [22] Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis
    Tetsuya Ikawa
    Takuya Miyagawa
    Yuki Fukui
    Satoshi Toyama
    Jun Omatsu
    Kentaro Awaji
    Yuta Norimatsu
    Yusuke Watanabe
    Ayumi Yoshizaki
    Shinichi Sato
    Yoshihide Asano
    Arthritis Research & Therapy, 23
  • [23] Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
    Jessen, H.
    Hoyer, N.
    Prior, T. S.
    Frederiksen, P.
    Karsdal, M. A.
    Leeming, D. J.
    Bendstrup, E.
    Sand, J. M. B.
    Shaker, S. B.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [24] Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
    H. Jessen
    N. Hoyer
    T. S. Prior
    P. Frederiksen
    M. A. Karsdal
    D. J. Leeming
    E. Bendstrup
    J. M. B. Sand
    S. B. Shaker
    Respiratory Research, 22
  • [25] The type I interferon induced protein IFIT-2 contributes to type I interferon mediated proinflammatory immune response
    Siegfried, A.
    Berchtold, S.
    Manncke, B.
    Ott, T.
    Autenrieth, I. B.
    Bohn, E.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 301 : 46 - 46
  • [26] A case of Buerger's disease with vasculopathy and skin fibrosis requiring differential diagnosis from systemic sclerosis
    Funada, Masashi
    Nakayamada, Shingo
    Fukuyo, Shunsuke
    Kubo, Satoshi
    Nawata, Aya
    Fujita, Yuya
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY CASE REPORTS, 2024,
  • [27] EVIDENCE OF TYPE I INTERFERON ACTIVATION DURING VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS
    Di Donato, S.
    Hughes, M.
    Abignano, G.
    Lettieri, G.
    Ross, R.
    De Lorenzis, E.
    O'Connor, P.
    Kubassova, O.
    Del Galdo, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1200 - 1200
  • [28] EVIDENCE OF TYPE I INTERFERON ACTIVATION DURING VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS
    Di Donato, Stefano
    Hughes, Michael
    Geloshi, Klaudian
    De Lorenzis, Enrico
    Kakkar, Vishal
    Ross, Rebecca
    O'Connor, Philip
    Kubassova, Olga
    Del Galdo, Francesco
    RHEUMATOLOGY, 2023, 62
  • [29] Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?
    Minghua Wu
    Shervin Assassi
    Current Treatment Options in Rheumatology, 2021, 7 : 349 - 360
  • [30] Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?
    Wu, Minghua
    Assassi, Shervin
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2021, 7 (04) : 349 - 360